Q: Hi 5i, First thanks for all the feedback on WELL, but I was hoping for a little more information on the performance, valuation and growth aspect for WELL. Earlier I asked if the one analysts view on valuation and direction of company from a pure tech play to a mix of primary care made any sense. I've always been of the opinion that they were a more tech play. Also if you have any pier/competitor comparisons that woul be great. Thanks again for all your assistance.
5i Research Answer:
With its 'digitization' of the healthcare industry, WELL is seen as a hybrid of tech/health. But, its future growth may depend on patient interactions, and it has been highlighting these, so it may be transitioning to more 'health'. This could in fact be a reason for some of the stock's weakness. It is currently 17X earnings and 1X forward sales. Valuation history is less of use since it had been losing money in earlier years. DCGO is a similar size peer, not exactly the same, but trades at 36X earnings. TDOC is larger, and has falled a long way down, also trades at 1X sales but is losing money so no P/E.